Literature DB >> 23241742

Pluripotent stem cells: immune to the immune system?

Jeremy I Pearl1, Leslie S Kean, Mark M Davis, Joseph C Wu.   

Abstract

Human embryonic stem cells (hESCs), initially thought to be immune privileged cells, are now known to be susceptible to immune recognition. Human induced pluripotent stem cells (iPSCs) have been proposed as a potential source of autologous stem cells for therapy, but even these autologous stem cells may be targets of immune rejection. With clinical trials on the horizon, it is imperative that the immunogenicity of hESCs and iPSCs be definitively understood.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23241742      PMCID： PMC3638038          DOI： 10.1126/scitranslmed.3005090

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  30 in total

1.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.

Authors:  T Kawai; D Andrews; R B Colvin; D H Sachs; A B Cosimi
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Embryonic stem cell trials for macular degeneration: a preliminary report.

Authors:  Steven D Schwartz; Jean-Pierre Hubschman; Gad Heilwell; Valentina Franco-Cardenas; Carolyn K Pan; Rosaleen M Ostrick; Edmund Mickunas; Roger Gay; Irina Klimanskaya; Robert Lanza
Journal:  Lancet       Date:  2012-01-24       Impact factor: 79.321

3.  Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells.

Authors:  Jeremy I Pearl; Andrew S Lee; Dennis B Leveson-Gower; Ning Sun; Zhumur Ghosh; Feng Lan; Julia Ransohoff; Robert S Negrin; Mark M Davis; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

4.  Immunogenicity of induced pluripotent stem cells.

Authors:  Tongbiao Zhao; Zhen-Ning Zhang; Zhili Rong; Yang Xu
Journal:  Nature       Date:  2011-05-13       Impact factor: 49.962

Review 5.  Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.

Authors:  Jeffrey R Curtis; Jasvinder A Singh
Journal:  Clin Ther       Date:  2011-06       Impact factor: 3.393

Review 6.  The role of Fas ligand in immune privilege.

Authors:  D R Green; T A Ferguson
Journal:  Nat Rev Mol Cell Biol       Date:  2001-12       Impact factor: 94.444

7.  Human leukocyte antigen I knockdown human embryonic stem cells induce host ignorance and achieve prolonged xenogeneic survival.

Authors:  Tobias Deuse; Martina Seifert; Neil Phillips; Andrew Fire; Dolly Tyan; Mark Kay; Philip S Tsao; Xiaoqin Hua; Joachim Velden; Thomas Eiermann; Hans-Dieter Volk; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

8.  GRNOPC1: the world's first embryonic stem cell-derived therapy. Interview with Jane Lebkowski.

Authors:  Jane Lebkowski
Journal:  Regen Med       Date:  2011-11       Impact factor: 3.806

9.  Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells.

Authors:  Kanishka Mohib; David Allan; Lisheng Wang
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

10.  Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells.

Authors:  Beatriz Suárez-Alvarez; Ramón M Rodriguez; Vincenzo Calvanese; Miguel A Blanco-Gelaz; Steve T Suhr; Francisco Ortega; Jesus Otero; Jose B Cibelli; Harry Moore; Mario F Fraga; Carlos López-Larrea
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240
View more
  29 in total

Review 1.  Current Challenges and Solutions to Tissue Engineering of Large-scale Cardiac Constructs.

Authors:  Yu-Chun Chang; Gabriel Mirhaidari; John Kelly; Christopher Breuer
Journal:  Curr Cardiol Rep       Date:  2021-03-17       Impact factor: 2.931

Review 2.  Training stem cells for treatment of malignant brain tumors.

Authors:  Shengwen Calvin Li; Mustafa H Kabeer; Long T Vu; Vic Keschrumrus; Hong Zhen Yin; Brent A Dethlefs; Jiang F Zhong; John H Weiss; William G Loudon
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

3.  Efficient Generation of Functionally Active Spinal Cord Neurons from Spermatogonial Stem Cells.

Authors:  Hao Yang; Cuicui Liu; Bo Chen; Jing An; Rui Zhang; Qian Zhang; Jingjing Zhao; Baorong He; Ding-Jun Hao
Journal:  Mol Neurobiol       Date:  2016-08-26       Impact factor: 5.590

Review 4.  Induced pluripotent stem cell technology: a decade of progress.

Authors:  Yanhong Shi; Haruhisa Inoue; Joseph C Wu; Shinya Yamanaka
Journal:  Nat Rev Drug Discov       Date:  2016-12-16       Impact factor: 84.694

Review 5.  Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.

Authors:  Angelos Oikonomopoulos; Tomoya Kitani; Joseph C Wu
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

6.  Human Parthenogenetic Embryonic Stem Cell-Derived Neural Stem Cells Express HLA-G and Show Unique Resistance to NK Cell-Mediated Killing.

Authors:  Jessica Schmitt; Sigrid Eckardt; Paul G Schlegel; Anna-Leena Sirén; Valentin S Bruttel; K John McLaughlin; Jörg Wischhusen; Albrecht M Müller
Journal:  Mol Med       Date:  2015-03-23       Impact factor: 6.354

Review 7.  Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.

Authors:  Patricia K Nguyen; Evgenios Neofytou; June-Wha Rhee; Joseph C Wu
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

8.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

Review 9.  Immunogenicity of pluripotent stem cells and their derivatives.

Authors:  Patricia E de Almeida; Julia D Ransohoff; Abu Nahid; Joseph C Wu
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

10.  HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.

Authors:  Zaruhi Karabekian; Hao Ding; Gulnaz Stybayeva; Irina Ivanova; Narine Muselimyan; Amranul Haque; Ian Toma; Nikki G Posnack; Alexander Revzin; David Leitenberg; Michael A Laflamme; Narine Sarvazyan
Journal:  Tissue Eng Part A       Date:  2015-09-10       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.